2017
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effects
2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83: 134-141. PMID: 24907236, PMCID: PMC4117168, DOI: 10.1212/wnl.0000000000000564.Peer-Reviewed Original ResearchConceptsHigher CPE scoreLower CPE scoreAntiretroviral therapy regimenProgressive multifocal leukoencephalopathyCPE scoreHIV dementiaHazard ratioCryptococcal meningitisMultifocal leukoencephalopathyTherapy regimenAntiretroviral therapy-naive individualsCNS penetration-effectiveness (CPE) scoreTherapy-naive individualsRespective hazard ratiosCases of toxoplasmosisHIV-CAUSAL CollaborationIncidence of AIDSAntiretroviral penetrationAntiretroviral regimenBaseline regimensInitial regimenNeurologic conditionsNeurologic disordersCNS penetrationRegimen
2007
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies
Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21: 1579-1589. PMID: 17630553, PMCID: PMC3460378, DOI: 10.1097/qad.0b013e3281532b31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCD4 Lymphocyte CountCohort StudiesCyclopropanesDrug Administration ScheduleFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPatient ComplianceReverse Transcriptase InhibitorsRNA, ViralTreatment OutcomeVeteransViral LoadConceptsPrevious antiretroviral exposureSingle PI regimensCombination ARTImmunological outcomesAntiretroviral exposureHIV RNAPI regimensProtease inhibitorsCombination antiretroviral therapy regimenHIV-RNA viral suppressionTreatment assignmentVeterans Affairs Healthcare SystemEfavirenz-based regimenGreater adherence levelsLog HIV RNAAntiretroviral therapy regimenBaseline clinical characteristicsCD4 cell countCombination antiretroviral therapyPharmacy refill recordsOutcome one yearAntiretroviral prescriptionsAntiretroviral regimensEfavirenz regimensNevirapine regimens